Please provide your email address to receive an email when new articles are posted on . This patient population had “better outcomes” when receiving benralizumab with or without prednisolone vs.

Benralizumab is noninferior to mepolizumab for the treatment of patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis receiving standard of care. Benralizumab is ...

At the recent American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, researchers reported that treatment with benralizumab (Fasenra) was noninferior to mepolizumab (Nucala) for ...

Learn everything you need to know about Benralizumab-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...

Please provide your email address to receive an email when new articles are posted on . The safety of benralizumab showed no “meaningful difference” compared with mepolizumab. Benralizumab only ...

A year's course of benralizumab injections has led to a significant decrease in the frequency of asthma exacerbations -- cutting the rate of exacerbations by a third to a half compared with placebo ...

MILAN -- Benralizumab (Fasenra) allowed patients with severe eosinophilic asthma to reduce inhaled corticosteroid (ISC) use without compromising control, the SHAMAL phase IV randomized trial found.

Use of benralizumab led to significant improvements in CT mucus scores and asthma control over 2.5 years, as indicated by data from 29 individuals with eosinophilic asthma. "Mucus-plug formation in ...

The 56-week OSTRO trial evaluated the efficacy and safety of benralizumab, an interleukin-5 antagonist, in 413 adult patients with severe nasal polyposis. Treatment with benralizumab was associated ...

For patients with severe eosinophilic asthma controlled on bevacizumab, tapering of inhaled corticosteroids (ICS) is feasible and is not associated with worse asthma control, according to a study ...

• Benralizumab comes as an injection which is available as a single dose prefilled syringe to be administered subcutaneously or just under the skin. • Benralizumab should be allowed to warm at room ...

The appraisal committee considered evidence submitted by AstraZeneca and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.